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Abstract. Antivenoms manufactured by bioCSL Limited (Australia) and Instituto Clodomiro Picado (Costa Rica)
against the venom of the taipan snakes (Oxyuranus scutellatus) from Australia and Papua New Guinea (PNG), respec-
tively, were compared using antivenomics, an analytical approach that combines proteomics with immunoaffinity chro-
matography. Both antivenoms recognized all venom proteins present in venom from PNG O. scutellatus, although a
pattern of partial recognition was observed for some components. In the case of the Australian O. scutellatus venom,
both antivenoms immunorecognized the majority of the components, but the CSL antivenom showed a stronger pattern
of immunoreactivity, which was revealed by the percentage of retained proteins in the immunoaffinity column.
Antivenoms interacted with taipoxin in surface plasmon resonance. These observations on antivenomics agree with
previous neutralization studies.
INTRODUCTION
Snakebite envenoming is a significant burden on the public
health system in Papua New Guinea (PNG).1–3 Three species
are responsible for the majority of cases: Acanthophis laevis
(smooth-scaleddeathadder),Micropechis ikaheka (NewGuinea
small-eyed snake), and Oxyuranus scutellatus (Papuan taipan).
Lower numbers of cases are induced by other Acanthophis
species, Pseudechis papuanus (Papuan blacksnake), and
Pseudonaja textilis (New Guinea brownsnake).3 In southern
PNG and southern Papua, the vast majority of snakebites are
inflicted by O. scutellatus.3 Envenomings by this large elapid
snake are characterized by minor local effects and severe sys-
temic manifestations, including irreversible flaccid paralysis,
coagulopathy associated with systemic spontaneous bleeding,
myotoxicity, acute kidney injury, and cardiac damage.2–6
The therapy for envenomings by O. scutellatus in PNG is
based on the intravenous administration of either CSL Poly-
valent Antivenom or CSL Taipan Antivenom (both manufac-
tured by bioCSL Limited in Melbourne, Victoria, Australia;
CSL). They are F(ab’)2 antivenoms generated by pepsin diges-
tion and ammonium sulphate precipitation of plasma of
hyperimmunized horses.3 Both of these antivenoms, when
administered early, have been shown to be effective in halting
coagulopathy and bleeding and reduce the incidence of respi-
ratory paralysis. CSL Polyvalent Antivenom is a polyspecific
mixture of immunoglobulins (Igs) raised against the venom
of Australian elapid species from five genera (Acanthophis,
Notechis, Oxyuranus, Pseudechis, and Pseudonaja). Although
CSL Taipan Antivenom is therapeutically indicated only for
treating envenoming by snakes of the genus Oxyuranus, this
antivenom is also the result of hyperimmunizing horses with
venom from the same five genera of Australian elapid snakes
used in production of CSL Polyvalent Antivenom.7 Recently, a
new, truly monospecific taipan antivenom has been prepared at
Instituto Clodomiro Picado (ICP) at the University of Costa
Rica (San Jose´, Costa Rica) against the venom ofO. scutellatus
from PNG. It is a whole-IgG preparation generated by caprylic
acid fractionation of the plasma of horses immunized with this
venom.8 A comparative pre-clinical assessment of the ability of
ICP and bioCSL antivenoms to neutralize the venom of PNG
taipan revealed a similar potency for the neutralization of
lethality and myotoxicity in mouse tests and phospholipase A2
(PLA2) activity, although the ICP whole-IgG antivenom
showed a higher efficacy in the neutralization of in vitro coag-
ulant activity.8 These antivenoms are currently being tested in
a randomized trial to assess their safety and efficacy in the
clinical setting.
In addition to tests designed to evaluate the ability of
antivenoms to neutralize toxic effects by venoms, the arena of
pre-clinical antivenom testing has been enriched in the last few
years with the development of antivenomics (i.e., the applica-
tion of proteomic tools to the analysis of the immunoreactivity
of antivenoms).9–13 Antivenomics bring information on which
venom components are recognized by antivenom antibodies
and which ones are not bound by antibodies, thus allowing a
fine characterization of the reactivity profile of antivenoms.
A prerequisite to perform antivenomics is the characterization
of the proteomes of the venoms to be analyzed. The proteomes
of the venoms of populations of O. scutellatus from PNG and
Australia have been recently characterized.14 The most abun-
dant components are PLA2s, including the potent pre-synaptic
neurotoxic complex taipoxin15 and other monomeric PLA2s.
16,17
In addition, these venoms contain Kunitz-type inhibitors,
neurotoxins of the three-finger family, serine proteinases,
metalloproteinases, cysteine-rich secretory proteins (CRISPs),
and the prothrombin activator Oscutarin-C.14,18 C-type lectin-
like proteins and venom natriuretic peptide were identified
only in the venom from PNG.14 This proteomic characteriza-
tion paves the way for investigating the antivenomics of
the two antivenoms prepared against O. scutellatus venoms.
This study presents an antivenomic analysis of the taipan
antivenoms manufactured by bioCSL and ICP and correlates
these findings with the previous pre-clinical study of the neu-
tralizing profile of these antivenoms.
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MATERIALS ANDMETHODS
Venoms and taipoxin. The venom of O. scutellatus from
PNG was a pool obtained from 12 healthy adult specimens
collected in theMilne Bay and Central Provinces in PNG. These
snakes were maintained in a purpose-built serpentarium at the
University of PNG, and venomwas collected at 21-day intervals.
Venom was obtained using Parafilm-covered Eppendorf tubes
and snap-frozen to −80°C before being freeze-dried and stored
in the dark at −20°C. The venom of Australian O. scutellatus as
well as the venoms of Pseudechis colletti and Notechis scutatus
were obtained from Venom Supplies Pty Limited (Tanunda,
South Australia, Australia). In some experiments, a preparation
of taipoxin provided by Ivan Kaiser was used.
Antivenoms. Two antivenoms were used in this study.
(1) Polyspecific taipan antivenom manufactured by bioCSL
Limited (CSL), Melbourne, Victoria, Australia (batch
B0548-06301; expiration date March of 2012). CSL taipan
antivenom contains a mixture of Igs with activity against
venoms from Acanthophis, Notechis, Oxyuranus, Pseudechis,
and Pseudonaja but with a minimum of 12,000 neutralizing
units of activity to Oxyuranus venom.7 (2) Monospecific
taipan antivenom manufactured by ICP (batch 4511209; expi-
ration date November of 2012). The physicochemical charac-
teristics and neutralizing potency of these antivenoms were
described by Vargas and others.8 CSL antivenom is made of
F(ab’)2 antibody fragments prepared by pepsin digestion and
ammonium sulphate precipitation. ICP antivenom is a whole-
IgG preparation obtained by caprylic acid precipitation of
non-IgG plasma proteins.8
Antivenomics: immunoaffinity chromatography. A modi-
fication of the second generation antivenomics protocol
described by Pla and others12 was followed. Immunoaffinity
columns of antivenoms were prepared by incubating 3 g
N-hydroxysuccinimide (NHS)-activated Sepharose with 100 mg
antivenom protein overnight. Non-reacting groups were
blocked for 2 hours with 0.2 M glycine, and the gel was packed
in a column and washed alternately at high and low pH values
with coupling buffer (0.1 M NaHCO3 and 0.5 M NaCl, pH 8.3)
and acetate buffer (0.1 M sodium acetate and 0.5 M NaCl, pH
4.0). Finally, the columns were equilibrated with 0.14 M NaCl
and 0.04 M phosphate (pH 7.2) solution (phosphate-buffered
saline [PBS]). A column coupled with equine normal IgG puri-
fied by caprylic acid fractionation of normal horse plasma was
used as control. For immunoaffinity assays, 5 mg O. scutellatus
venom from either Australia or PNGwas dissolved in 2 mL PBS
and passed through each column. The non-retained fraction of
proteins was eluted with PBS, and the retained proteins were
then eluted with 0.1 M glycine (pH 3). The pH of the fractions
was then neutralized with 1 M NaOH. In addition and for com-
parative purposes, the immunoreactivity of both antivenoms
against the venoms of P. colletti andN. scutatus was also studied
using an identical antivenomics protocol.
Non-retained and retained immunoaffinity fractions of the
venoms ofO. scutellatus were analyzed by reverse-phase high-
pressure liquid chromatography (HPLC) using a C18 column
(250 + 4.6 mm, 5-mm particle size; Agilent) and an Agilent
1100 system. For the elution of proteins, a flow of 1 mL
buffer/minute was used with the following conditions. The
column was equilibrated with buffer A (0.1% trifluoroacetic
acid [TFA] and 5% acetonitrile). Then, the following gradient
was developed: 5% buffer B of 95% acetonitrile and 0.1%
TFA for 10 minutes followed by 5–15% buffer B over
20 minutes, 15–45% buffer B over 120 minutes, and 45–70%
buffer B over 20 minutes. Proteins were detected at 215 nm.
Proteins were identified on the basis of the previous charac-
terization of the proteomes of these venoms.14 To have a
quantitative estimation of the extent of protein binding to
the affinity column, the areas of the peaks of retained and
non-retained fractions in the chromatogram were quantified,
and the percentage of retained fraction was estimated by the
equation: % retained = 100 – [(non-retained/(retained + non-
retained)) + 100].12
Quantification of specific antitaipan venom antibodies in
the antivenoms. An enzyme-linked immunosorbent assay
(ELISA) was developed for the quantification of antitaipan
venom antibodies in the antivenom. A standard of antitaipan
antibodies was obtained by affinity chromatography. Briefly,
a volume of either ICP or CSL antivenom was passed through
a column in which O. scutellatus venom from PNG had been
coupled as a ligand. After elution of the non-retained fraction,
the retained fraction (i.e., the antibodies that bound to venom
components in the column) was eluted with 0.1 M glycine
(pH 3.0), and the pH of the eluate was neutralized with 1 M
NaOH. The concentration of specific antitaipan antibodies
in antivenoms was determined in an ELISA using as a stan-
dard the affinity-purified antitaipan venom antibodies. Plates
were coated with 3 mg PNG O. scutellatus venom dissolved in
100 mL PBS per well. The plates were then incubated at room
temperature for 1 hour with various dilutions of each anti-
venom in 2% milk/PBS. In other wells, known amounts of
the affinity-purified antivenom antibody standards [either
IgG from ICP antivenom or F(ab’)2 from CSL antivenom]
were added. Plates were then washed five times with distilled
water. An anti-horse IgG peroxidase conjugate, diluted
1:6,000 with 2% milk/PBS, was later added, the plates were
incubated for 1 hour at room temperature, which was followed
by another washing step, and then, o-phenylenediamine and
H2O2 were added. Absorbance values at 492 nmwere recorded
using a microplate reader. A calibration curve was prepared by
plotting the absorbance of the affinity-purified antibodies
against taipan venom as a function of their corresponding anti-
body concentration to calculate the concentration of specific
antivenom IgGs (in ICP antivenom) or F(ab’)2 fragments
(in CSL antivenom) in the whole antivenoms. Specific antibody
concentrations were expressed in milligrams per milliliter, and
the percentage of antivenom antibodies in the whole anti-
venom was then estimated.
Surface plasmon resonance assays. Interactions between
taipoxin and antivenoms were assessed by surface plasmon
resonance (SPR) with a BIAcore T100 system. After sensor
chip docking, the instrument was primed three times with
10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), 150 mM NaCl, 3.4 mM (ethylenedinitrilo)tetra-
acetic acid (EDTA), and 0.005% Tween 20 (pH 7.4; HBS-P)
as running buffer, and the biosensor detector response was
normalized (automated procedure). Lyophilized taipoxin was
suspended and adjusted to 2 mM in 10 mM sodium acetate
(pH 4.5) and then covalently immobilized on a BIAcore
CM-5 sensor chip (carboxymethylated dextran matrix) accord-
ing to the manufacturer´s instructions. Briefly, the CM-5
chip was activated with a 1:1 mixture of 0.4 M 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide and 0.1 M N-hydroxy-
succinimide for 7 minutes. Taipoxin in 10 mM sodium acetate
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(pH 4.5) was injected over the activated CM-5 chip at 25°C.
Remaining active groups on the matrix were blocked with 1 M
ethanolamine/HCl (pH 8.5). Immobilization on the CM-5
sensor chip resulted in an average surface taipoxin concentra-
tion of 4.1 ng/mm2. A flow chamber subjected to the immobi-
lization protocol but without any addition of protein was used
as a reference surface (blank cell) for each experiment. Sam-
ples of ICP or CSL antivenoms at a concentration of 20 mg/mL
in HBS-P were injected over the immobilized and control
surfaces at a flow rate of 20 mL/minute for 2 minutes at 25°C
followed by a dissociation time of 300 seconds. Surface regen-
eration was performed with a single injection of 10 mM
glycine-HCl (pH 2.0) for 30 seconds at a flow rate of 100 mL/
minute followed by a wash step using running buffer at the
same flow rate for 750 seconds. Between experiments, an addi-
tional cycle was performed using only running buffer instead of
antivenom, because this extra cycle provides a more effective
surface regeneration, improving reproducibility. All results
were analyzed using Biaevaluation software (version 1.1.1),
and sensorgrams were processed by subtracting data from the
reference surface and adjusting the response on the y axis
(baseline). Individual experiments were performed three times
for each antivenom.
RESULTS
Antivenomics: immunoaffinity chromatography. Reverse-
phase HPLC separation of O. scutellatus venoms from PNG
and Australia was very similar to the separation previously
described in the proteomic characterization of these
venoms14; therefore, the numbering of fractions used in this
previous publication will be followed here (Figures 1A, 2A,
3A, and 4A). Antivenomics analysis showed that both
antivenoms were able to immunocapture the proteins present
in all the chromatographic peaks of the venom of taipan from
PNG (Figures 1B and 2B). Some fractions were completely
immunocaptured, but various fractions were only partially
immunocaptured by the antivenoms (i.e., fractions contain-
ing the PLA2 OS1 and taipoxin a- and g-chains [peak 17 in
Figures 1C and 2C] and a PLA2 and taipoxin a-chain [peak 16
in Figures 1C and 2C]). However, a fraction containing
taipoxin b-chain (peak 15 in Figures 1C and 2C) and a neuro-
toxin of the three-finger family (peak 1 in Figures 1C and 2C),
which were completely immunocaptured by CSL antivenom,
were partially recognized by the ICP antivenom (Figure 1C).
The estimation of the percentage of retained proteins of
the most abundant peaks in the HPLC separation is shown
in Table 1.
Antivenomic analysis of the venom of O. scutellatus from
Australia revealed that both antivenoms recognized all pro-
tein peaks, with the exception of a fraction corresponding to a
three-finger–type neurotoxin that was not immunocaptured
by ICP antivenom (peak 1 in Figure 3B and C). Analysis of
the chromatographic patterns of proteins that were not
completely immunocaptured revealed differences between
antivenoms. Fractions corresponding to serine proteinase
inhibitor subunit of taicatoxin (peaks 4 and 5 in Figure 3B
and C), PLA2s OS2 and OS7 (peak 7 in Figure 3B and C),
other PLA2s (peaks 8 and 9 in Figure 3B and C), and taipoxin
a-chain (peak 11 in Figure 3B and C) were only partially
immunocaptured by ICP antivenom. In the case of CSL anti-
venom, fractions that were partially immunocaptured were
serine proteinase inhibitor subunit of taicatoxin (peaks 4
and 5 in Figure 3B and C), PLA2s OS2 and OS7 (peak 7 in
Figure 3B and C), PLA2 OS6 (peak 13 in Figure 3B and C),
and taipoxin b- and g-subunits (peak 15 in Figure 3B and C).
A stronger pattern of immunorecognition of the venom of
O. scutellatus from Australia was observed for the CSL anti-
venom, because it showed a higher percentage of retained
proteins than ICP antivenom for the majority of the peaks
(Figures 3 and 4 and Table 2). When a control immunoaffinity
column, containing IgGs from horses non-immunized with
venoms, was used, the percentage of retained proteins was
negligible for the majority of the peaks. However, these con-
trol antibodies bound peaks 15 (20% retention) and 17 (22%
retention) in the venom from PNG O. scutellatus and peak 9
(20% retention) in the venom of Australian O. scutellatus
Figure 1. Antivenomics analysis of monospecific ICP taipan anti-
venom with the venom of O. scutellatus from PNG. Chromatograms
represent (A) reverse-phase HPLC separations of venom proteins,
(B) venom proteins immunocaptured by the affinity column, and
(C) venom proteins not immunocaptured in the column (details in
Materials and Methods). The identification of proteins in each peak
is depicted in Table 1 based on the proteomic characterization
described in a previous study.14
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(not shown), evidencing the presence of antibodies in this
control equine serum with the ability to bind these venom
components, all of which correspond to PLA2s, including
some taipoxin chains.
Because ICP antivenom is a truly monospecific taipan anti-
venom, whereas CSL taipan antivenom is produced from the
plasma of horses immunized with venoms from snakes of
various genera, we assessed whether these antivenoms would
immunoreact differently against venoms of species different
from O. scutellatus. To this end, the immunoaffinity columns
containing antibodies from taipan antivenoms were used
to analyze their immunoreactivity against the venoms of
P. colletti and N. scutatus. As shown in Figure 5, CSL taipan
antivenom has a much stronger pattern of immunorecognition
of these venoms than ICP antivenom, which is in agreement
with the polyspecific nature of the former.
Quantification of specific antitaipan venom antibodies in
antivenoms. An ELISA was developed to estimate the con-
centration of specific anti-PNG taipan venom antibodies in
antivenoms. The concentrations of specific antibodies were
13.0 ± 1.8 and 23.2 ± 3.8 mg/mL for ICP and CSL antivenoms,
respectively. Taking into account that the total protein con-
centrations in these antivenoms are 45.9 ± 0.9 and 144.6 ±
0.4 mg/mL, respectively, the percentages of total protein in
each antivenom corresponding to specific antitaipan venom
antibodies are 28.3% and 16.0% for ICP and CSL anti-
venoms, respectively.
Interactions studied by SPR. We examined the interaction
of antivenoms with taipoxin by the SPR technology using a
sensor chip on which the toxin had been immobilized. Figure 6
shows that antivenoms ICP and CSL (at 20 ng/mL) bound to
Figure 3. Antivenomics analysis of monospecific ICP taipan anti-
venom with the venom of O. scutellatus from Australia. Chromato-
grams represent (A) reverse-phase HPLC separations of venom
proteins, (B) venom proteins immunocaptured by the affinity column,
and (C) venom proteins not immunocaptured in the column (details
in Materials and Methods). The identification of proteins in each
peak is depicted in Table 2 based on the proteomic characterization
described in a previous study.14
Figure 2. Antivenomics analysis of polyspecific CSL taipan anti-
venom with the venom of O. scutellatus from PNG. Chromatograms
represent (A) reverse-phase HPLC separations of venom proteins,
(B) venom proteins immunocaptured by the affinity column, and
(C) venom proteins not immunocaptured in the column (details
in Materials and Methods). The identification of proteins in each
peak is depicted in Table 1 based on the proteomic characterization
described in a previous study.14
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the immobilized toxin; however, ICP showed higher affinity
for taipoxin, indicating that it may contain either a higher con-
centration of antitaipoxin antibodies or antibodies of higher
affinity for this toxin.
DISCUSSION
Antivenomics has become a useful tool to identify compo-
nents in venoms that are either recognized or not recognized
by antibodies or antibody fragments in antivenoms.10,11,13 First
generation antivenomics were based in the immunoprecipita-
tion of antigen–antibody complexes, with additional identifica-
tion of non-immunoreacting proteins in the supernatant.9,19
Second generation antivenomics use affinity chromatography
to separate immunoreacting and non-immunoreacting venom
proteins.12 The latter technique has several advantages over
first generation antivenomics, such as the possibility of analyz-
ing not only IgG antivenoms but also antivenoms made of
antibody fragments and the fact that both immunocaptured
and non-immunocaptured venom components can be ana-
lyzed.12 Antivenomics provide additional information to the
pre-clinical neutralization tests and have become a tool to
gain a deeper understanding of antivenom reactivity by also
allowing a knowledge-based selection of venoms to be included
in immunizing mixtures for the manufacture of antivenoms.10
Our antivenomics results show a qualitatively similar pro-
file of these two antivenoms when tested with the venom of
O. scutellatus from PNG, although quantitative differences
in the percentages of proteins were noticed in several peaks.
All venom fractions were recognized by the antivenoms, but
there were several components, mostly the PLA2 OS1 and
some taipoxin subunits, that were partially recognized. In
addition, a peak containing a three-finger neurotoxin was
partially immunorecognized by ICP antivenom but totally
immunocaptured by the CSL antivenom. In the case of
O. scutellatus venom from Australia, CSL antivenom showed
a stronger pattern of immunorecognition than ICP anti-
venom. Although all fractions were retained by the two
antivenoms, with the exception of a neurotoxin of the three-
finger family that was not recognized by ICP antivenom, the
HPLC profile of non-bound protein peaks revealed higher
peaks of non-retained fractions in the case of ICP antivenom,
which was quantitatively reflected in lower percentages of
retained proteins. These fractions correspond to PLA2s,
including OS2 and OS7, and two chains of taipoxin. One
possibility is that these antivenomics data might be revealing
immunological differences between the venoms of popula-
tions ofO. scutellatus from PNG and Australia. Alternatively,
the observed differences may, instead, depend on the fact
that CSL antivenoms are generated from groups of horses
immunized with different types of venoms at different times
(i.e., they are, indeed, polyspecific antivenoms). In contrast,
ICP antivenom is monospecific, because horses are immu-
nized only with PNG O. scutellatus venom. This result was
corroborated in this study, because CSL taipan antivenom
Table 1
Percentages of retained proteins in the most abundant HPLC fractions of O. scutellatus venom from PNG after immunoaffinity with ICP and
CSL taipan antivenoms (details in Materials and Methods)
HPLC peak number* Types of proteins1 ICP (% retained fraction) CSL (% retained fraction)
1 Three-finger toxin 61 100
5 Kunitz-type proteinase inhibitor (subunit of taicatoxin) 81 82
14 PLA2 (OS7 precursor), natriuretic protein 88 91
15 PLA2 (taipoxin b-chain) 81 100
16 PLA2 (taipoxin a-chain) 54 45
17 PLA2 (taipoxin g-chain, OS1) 55 34
18 PLA2 (taipoxin g-chain) 100 100
*The peak number and the identification of the proteins present in each peak correspond to those described in a previous study.14
Figure 4. Antivenomics analysis of polyspecific CSL taipan anti-
venom with the venom of O. scutellatus from Australia. Chromato-
grams represent (A) reverse-phase HPLC separations of venom
proteins, (B) venom proteins immunocaptured by the affinity column,
and (C) venom proteins not immunocaptured in the column (details
in Materials and Methods). The identification of proteins in each
peak is depicted in Table 2 based on the proteomic characterization
described in a previous study.14
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reacted strongly with the venoms of P. colletti and N. scutatus,
whereas ICP antivenom showed a much lower pattern of
recognition of these venoms. Therefore, the presence of anti-
bodies against some fractions of the Australian O. scutellatus
venom that are recognized by CSL antivenom but not ICP
antivenom might be the consequence of immunization with
other elapid venoms containing high concentrations of toxins
that cross-react with O. scutellatus venom components, such
as neurotoxins of the three-finger family.
It is relevant to correlate these antivenomics findings
with the previously described neutralizing ability of these
antivenoms.8 In general terms, the widespread immuno-
recognition revealed by antivenomics correlates with the
capacity of these two antivenoms to neutralize lethal, coagu-
lant, myotoxic, and PLA2 activities of PNG and Australian
O. scutellatus venoms.8,14 Moreover, these antivenomic pat-
terns correlate with the lethality neutralization tests previ-
ously described, because these antivenoms present similar
potencies (in terms of milligrams of venom neutralized per
milliliter antivenom) for the venom of PNG O. scutellatus,
whereas the CSL antivenom has a higher potency than ICP
antivenom when pre-incubated with O. scutellatus venom
from Australia.14 The ability of antivenoms to neutralize the
lethal effect of O. scutellatus venom depends, to a large
extent, on their capacity to neutralize taipoxin, the most
potent neurotoxin in the venoms of both populations of
taipan.15,20 In this regard, the two antivenoms bound taipoxin
a-, b-, and g-subunits to varying degrees in venoms from both
PNG and Australian O. scutellatus in the affinity column. In
addition, SPR observations corroborated the ability of both
antivenoms to bind taipoxin, with a higher affinity in the ICP
antivenom. Neutralization of short-chain a-neurotoxins is also
important to ameliorating the lethality of O. scutellatus venoms,
and ICP antivenom is currently less efficient at achieving
immunocapturing of these toxins than CSL antivenom; strate-
gies for improvement are currently being considered.
Figure 5. Immunoaffinity chromatography analysis of polyspecific CSL and monospecific ICP taipan antivenoms with the venoms of P. colletti
andN. scutatus from Australia. Chromatograms represent reverse-phase HPLC separations of venom proteins of (A) P. colletti and (D)N. scutatus
and venom proteins immunocaptured by the affinity column of (B and E) CSL taipan antivenom and (C and F) ICP taipan antivenom (details
in Materials and Methods).
Table 2
Percentages of retained proteins in the most abundant HPLC fractions of O. scutellatus venom from Australia after immunoaffinity with ICP and
CSL taipan antivenoms (details in Materials and Methods)
HPLC peak number* Types of proteins ICP (% retained fraction) CSL (% retained fraction)
1 Three-finger toxin 3 100
4 Kunitz-type proteinase inhibitor (subunit of taicatoxin) 62 58
5 Kunitz-type proteinase inhibitor (subunit of taicatoxin) 58 58
7 PLA2 (OS1 and OS7 precursors) 19 72
8 PLA2 22 92
9 PLA2 39 94
11 PLA2 (taipoxin a-chain) 45 84
13 PLA2 (OS6 precursor) 76 34
15 PLA2 (taipoxin b- and g-chains) 53 24
*The peak number and the identification of the proteins present in each peak correspond to those described in a previous study.14
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Our previous studies indicated that, in terms of protein
concentration, ICP antivenom shows a higher neutralizing
capacity than CSL antivenom, because although they have
similar potencies against PNG O. scutellatus venom in terms
of milligrams of venom neutralized per milliliter of anti-
venom, ICP antivenom has higher potency in terms of milli-
grams of venom neutralized per milligram of antivenom
protein owing to differences in total protein concentration
(45.9 and 144.6 mg/mL for ICP and CSL antivenoms, respec-
tively).8 Our estimation of the concentration of specific anti-
O. scutellatus antibodies present in antivenoms provides a
partial explanation of this observation, because only 16% of
total proteins were specific anti-O. scutellatus venom antibod-
ies in the case of CSL antivenom, whereas it was 28% in the
case of ICP antivenom. This result might have to do with the
fact that ICP O. scutellatus antivenom is a truly monospecific
antivenom, whereas CSL antivenom has been shown to be
polyspecific, because horses have been also used for immuni-
zation with other Australian snake venoms. However,
although ICP antivenom shows a higher potency than CSL
antivenom in terms of milligrams of venom neutralized per
milligram of antivenom protein,8,14 our antivenomics analyses
highlighted a stronger pattern of immunoreactivity of CSL
antivenom against Australian O. scutellatus venom when the
same amount of antivenom protein is linked to the affinity
column. This apparent discrepancy might be caused by the
different conditions in which these two types of tests are per-
formed. In the neutralization tests, antivenom and venom
are incubated for 30 minutes before testing, whereas in anti-
venomics, the venom is passed through the affinity column.
Our findings stress the need to study the pre-clinical efficacy
of antivenoms by combining neutralization assays and
antivenomics. Such studies may be useful in predicting the
performance of candidate antivenoms at clinical trials, and
certainly, it is imperative that antivenoms be subjected to
well-designed clinical trials before they are marketed.
In addition to neurotoxicity leading to respiratory paraly-
sis, envenomings by O. scutellatus are characterized by coag-
ulopathy and associated spontaneous systemic bleeding.4
This effect is caused by the action of a group C prothrombin
activator, Oscutarin C, an oligomeric protein comprising factor
Xa-like and factor Va-like proteins.
18 Despite its pathophysio-
logical relevance in envenomings, this component is present in
relatively low concentration in the venom and therefore, diffi-
cult to identify in the overall proteome,14 which complicates the
antivenomic analysis of these procoagulants. Nevertheless, our
results show that peaks containing Oscutarin C, albeit minor,
were largely bound to the affinity column. The reason why ICP
antivenom shows a higher neutralizing ability than CSL anti-
venom against procoagulant activity of taipan venoms from
both populations8,14 was not answered by this antivenomics
study and thus, remains to be further investigated.
Kunitz-type protease inhibitors were identified in the
proteomes of taipan venoms.14 A Kunitz-type inhibitor con-
stitutes one of the subunits of taicatoxin, a protein that exerts
blocking effects in the membranes of cardiac muscle cells,21
although the role of this complex in the overall toxicity of
taipan venom is uncertain. Our observations indicate that the
HPLC fractions containing Kunitz-type inhibitors are recog-
nized by both antivenoms, although the corresponding peaks
were also observed in the unbound fractions in the case of
Australian taipan venom, thus reflecting a pattern of partial
immunological recognition.
The interpretation of these antivenomic results vis-a`-vis the
previous observations of effective neutralization of the lethal,
coagulant, myotoxic, and PLA2 activities of both venoms by
these antivenoms8,14 suggests that the patterns of partial
immunorecognition observed might imply effectiveness in
the neutralization of the venom components being recognized
in the affinity columns. In these cases, the conditions of the
neutralization experiments (i.e., the incubation of venom and
antivenom before testing in the corresponding pharmacologi-
cal or enzymatic systems) are likely to ensure that antibodies
against toxins that show a partial recognition pattern in
antivenomics bind and neutralize the corresponding toxins.
Therefore, the most critical finding in antivenomic studies
would be the presence of toxins that are not immuno-
recognized at all, because neutralization of these toxins in
in vivo experiments is highly unlikely. There was only one
such case observed in this study (i.e., a neurotoxin of the
three-finger family in the venom of Australian taipan was not
recognized at all by ICP antivenom). The role of this neuro-
toxin in the overall toxicity of the venom is unknown,
although it is likely to be secondary in light of the preponder-
ance of taipoxin in toxicity. Nevertheless, future improvement
of this antivenom should consider enhancing the antibody
titer against this neurotoxin.
In conclusion, the antivenomics results presented comple-
ment the pre-clinical assessment of these two taipan anti-
venoms.8,14 Results indicate that antivenoms recognize all
the proteins present in the venoms of O. scutellatus of PNG,
which is in agreement with previous pre-clinical results on the
neutralization of lethal, myotoxic, coagulant, and PLA2 activ-
ities. However, a pattern of stronger immunorecognition
was observed for the CSL antivenom when tested against
O. scutellatus venom from Australia. The combination of
Figure 6. Analysis of the interaction of taipoxin with ICP and CSL
antivenoms by SPR using the BIAcore T100 system. The antivenoms
at 20 mg/mL in HBS-P of 10 mM HEPES, 150 mM NaCl, 3.4 mM
EDTA, and 0.005% Tween 20 (pH 7.4) were injected over immo-
bilized taipoxin at a flow rate of 20 mL/minute. The value of zero
response corresponds to the baseline.
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antivenomics and toxicity neutralization tests provides com-
plementary information for a proper understanding of the
pre-clinical efficacy of antivenoms and is a useful tool for the
prediction of in vivo activity and the design of clinical studies
of these products.
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